FORMULATION, DEVELOPMENT AND OPTIMIZATION OF SUSTAINED RELEASE DELIVERY SYSTEM OF ANTI-PLATELET DRUGS

Shivesh Prasad Sinha; Dr.Manish Jaimini

doi:10.61280/tjpls.v9i3.101

Shivesh Prasad Sinha Department of Pharmacy Maharishi Arvind University, Jaipur
Dr.Manish Jaimini Department of Pharmacy, Mahrishi Arvind University, Jaipur

DOI: https://doi.org/10.61280/tjpls.v9i3.101

Keywords:

Antiplatelet, Cardiovascular diseases, Bilayered Tablets, Cilostazolas, Ticagrelor

Abstract

Antiplatelet medications currently on the market interfere with one or more phases in the platelet release and aggregation process, leading to a meaningful decrease in thrombosis risk that cannot be separated from an elevated risk of bleeding. Understanding that under physiological conditions, 1011 platelets are created daily-a quantity that can rise up to 10-fold during times of greater need—is crucial when thinking about antiplatelet medications.

Downloads

Download data is not yet available.

References

Reference:

Patel D, Patel A, Solanki T. Formulation and evaluation of bilayer tablet by using melt granulation technique for treatment of diabetes mellitus. J Pharm Bioallied Sci. 2012 Mar;4(Suppl 1):S37-9. doi: 10.4103/0975-7406.94135.

Hiten AP, Ajay Kumar T. A Novel approach of Bilayer Tablet technology: A Review. International Research journal of pharmacy, 2012, 5-10.

Manidipta D. Bilayer Tableting Technology: An Overview, Journal of Pharmacy Research, 25(1), 2012, 310-314.

Kotta kranthikumar, m. narasimhareddy, r.nagakishore. Formulation and evaluation of bilayermatrix tablet of pioglitazone hcl metformin hclusp 15mg&500mg.asaian journal of pharmaceutical and clinical reserch. vol 6, suppl 3, 2013.

Bagyalakshmi.J, Phani Krishna Y , Ravi T K. Bilayer tablet formulation of metformin hydrochloride and glipizide: a novel approach in the treatment of diabetes. volume 8, issue 2, may – june 2011; article-035.

Sadhana shahi, shantanushivanikar, nityanandzadbuke, abhaypadalkar. formulation and evaluation of bilayered tablet of metformin hydrochloride and pioglitazone hydrochloride. International journal of pharmacy and pharmaceutical sciences. issn- 0975-1491 vol 4, suppl 5, 2012.

PamuSandhya , Faheem Unnisa Begum , Afreen. Formulation and Evaluation of Bilayer Tablets of Glimepiride and Metformin HCL. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) .e-ISSN: 2278-3008, p-ISSN:2319-7676. Volume 9, Issue 1 Ver. IV (Jan. 2014), PP 38-45.

Akhilesh Tiwari,O.P.Mahatma, Megha Joshi. Formulation and Evaluation of Combined Floating Bilayer Tablet of Metformin, Pioglitazone and Glimepiride. International Journal of Pharmaceutical & Biological Archives. 2013; 4(4): 792 – 799.

Hemanth kumar.G, k. jaganathan, r. sambathkumar, p. perumal. Formulation and in-vitro evaluation of bilayer floating tablets of metformin hydrochloride and sitagliptin phosphate.Ijapjournal. Vol 2 | Issue 2 | 2012 | 64-81.

Nisarg Patel*, Dr.P.S.Naruka, Dr. Chetan Singh Chauhan, Jaimin Mod Formulation Development and Evaluation of Immediate Release Tablet of Topiramateanti Epileptic Drug JPSBR: Volume 3, Issue 2: March April 2013 (58- 65).

Natalie MC Clure (1997) Stability Studies in Overview of ICH Guidelines for Drug products, Matric Pharmaceutical Inc.

FDA/ICH Regulatory Guidance on Stability. In Federal Register, vol 63, Washington: Food & Drug Administration, 1998:9795–9843.

Sheinin EB. ICH Guidelines: History, Present Status, Intent. Athens, GA: International Good Manufacturing Practices Conference, 1998.

Tatsyoshi W, kyKyoko S, YutkaH ,ToshimasaT, Satoshi K. Solid state compatibility studies using a high-throughput and automated forced degradation system. Int. J. Pharm. 2008;3(55):164-73.

Kiss D, Zelko R, Novak Cs, Ehen Zs. Application of dsc and nirs to study the compatibility of Metronidazole with different pharmaceutical excpients. J Thermal Analysis and Calorimetry. 2006;84(2)447-51.

Pawar V K, Gaurav Sharma,GarimaGarg, Rajendra Awasthi, Giriraj T Kulkarni. Taste Masking of Promethazine hydrochloride using EudrajitE100 via Solid

dispersion technique to develop Fast Disintegerating Tablets. Der Pharmacia Lettre2010;2(3):83-94.

Prakash Khadka, Jieun R, HyeongminKim ,Iksoo Kim , Jeong Tae Kim , Hyunil Kim , Jae Min Cho , Gyiae Yun , Jaehwi Lee , a College of Pharmacy,Chung-Ang University, Seoul 156-756, Republic of Korea b Department of Food Science and Technology, Chung-Ang University, Anseong 456-756, Republic of Korea.

Samran et al., Samran1, Karson , Matheus TimbulSimanjuntak and Jansen Silalah: Optimised formulation of Metoclopramide orally Disintegerating tablets.

Y Gert van der Meer1, Willem A Venhuizen1, Daren K Heyland2 and Arthur RH van Zanten3 ,van der Meer et al.; licensee BioMed Central Ltd. 2014 Published: 23 September 2014.

Rogers KC, Oliphant CS, Finks SW. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015 Mar;75(4):377-95. doi: 10.1007/s40265-015-0364-3.

Chen PW, Tseng SY, Chang HY, Lee CH, Chao TH. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity. Int J Mol Sci. 2022 Aug 29;23(17):9768. doi: 10.3390/ijms23179768.

de Havenon A, Sheth KN, Madsen TE, Johnston KC, Turan TN, Toyoda K, Elm JJ, Wardlaw JM, Johnston SC, Williams OA, Shoamanesh A, Lansberg MG. Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. Stroke. 2021 Oct;52(10):e635-e645. doi: 10.1161/STROKEAHA.121.035002.

Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T; CSPS.com Study Investigators. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke. 2015 Feb;10(2):253-8. doi: 10.1111/ijs.12420. Epub 2014 Dec 8.

Hoshino H, Toyoda K, Omae K, Ishida N, Uchiyama S, Kimura K, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, Matsumoto M, Tominaga T, Tomimoto H, Terayama Y, Yasuda S, Yamaguchi T; CSPS.com Trial Investigators. Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial. Stroke. 2021 Nov;52(11):3430-3439. doi: 10.1161/STROKEAHA.121.034378.

Liss DB, Mullins ME. Antithrombotic and Antiplatelet Drug Toxicity. Crit Care Clin. 2021 Jul;37(3):591-604. doi: 10.1016/j.ccc.2021.03.012.

Chandrasekhar J, Baber U, Sartori S, et al. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol 2020; published online January 8. DOI:10.1007/s00392–019–01561–4.

Schüpke S, Neumann F-J, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019; 381: 1524–34.

Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for Oral P2Y12 inhibitors in primary PCI. N Engl J Med 2019; 381: 1621–31

Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.

Pathak N, Kumar A, Methkar V, Pant P, Rao RT. Formulation and optimization of immediate release tablet of an antialcoholic drug by dry granulation method. International Journal of comprehensive pharmacy. 2011; 2(3): 1-4.

Ujwala R. Bagmar*1, Pankaj S. Jadhav1 , Amit S. Lunkad1 , Shital G. Uttarwar2 , Sampada S. Jangam3 . Formulation and In-vitro Evaluation of Immediate Release Tablet of Fexofenadine Hydrochloride. Am. J. PharmTech Res. 2013; 3(3).

Santosh B. Jadhav* ,Audumber D. Mali, Swapnil H. Rajeghadage and Ritesh S. Bathe Formulation and evaluation of immediate release tablets of Imipramine hydrochloride IJBAR (2014) 05 (11)

Jigar A Patel1* , Jitendra S. Patel2 , Arjun Sony1 , Hemangi J Patel2 , Formulation and evaluation of immediate release tablet of azithromycin by dry granulation method using super disintegrants. American Journal of PharmTech Research. 2011; 1(4):211-218.

Wale Kiran K*1 ., Dr.Salunkhe K.S.1 , Sayyed S.F.1 , Dr. Chaudhari S.R1 ., Santosh Bhujbal1 formulation, development and in-vitro evaluation of immediate release tablet of sitagliptin phosphate monohydrate, Vol 3, Issue 3, 2014. 4945 23. Hitesh P. Patel*, Preeti Karwa, Rama Bukka, Nitesh J. Patel formulation and evaluation of immediate release tablets of zolpidem tartrate by direct compression, Volume 7, Issue 2, March – April 2011; Article-014.

Chen A, Shi Y, Yan Z, Hao H, Zhang Y, Zhong J, Hou H 1 . Dosage Form Developments of Nanosuspension Drug Delivery System for Oral Administration Route. Curr Pharm Des. 2015;21(29):4355-65.

Tiwari AK, Shah H, Rajpoot A, Singhal M. Formulation and in-vitro evaluation of immediate release tablets of drotaverine HCl. Journal of chemical and pharmaceutical research. 2011; 3(4): 333-341.

Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Scho¨mig A, Scho¨mig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. ThrombHaemost2004;92:311–6

Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin ThrombHemost1999;25:29–33

Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244–7

Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS II, Brandt JT, Darstein C, Jakubowski JA, Salazar DE. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin PharmacolTher2007;81:735–41

Md Sarfaraz1, 2 And V.G.Joshi1, 3 immediate release solid oral dosage form of salbuta Int J Pharm Pharm Sci, Vol 5, Issue 4, 610-618

Shafi Shaik* ,B.Pragathi Kumar, Harish.G Formulation and evaluation of immediate release Carvedilol tablets IJRPB 2(6) www.ijrpb.com NovemberDecember 2014 Page 1485.

https://www.rxlist.com/jentadueto-xr-drug.htm

Handbook of Pharmaceutical Excipients 6th Edition; Page No. 326-327

Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage systems. I: Preparation and in-vitro evaluation of floating and sustainedrelease characteristics. J Pharm Sci 1991; 80:1062-6.

Mitra SB. Sustained-Release Oral Medicinal Delivery Device. May 1984. US Patent No. 4,451,260.

Deray G, Bagnis C, Brouard R, Necciari J, Leenhardt AF, Raymond F, Baumelou A. Clopidogrel activities in patients with renal impairment. Clin Drug Invest 1998;16:319–28 1

Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 2000;40: 396–401.

Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a metaanalysis. Am J Med. 2008;121:43-49.

V. ForooqiMotlaq, F.A. Adlmann, V. Agmo Hernández, A. Vorobiev, M. Wolff, L.M. Bergström,Dissolution mechanism of supported phospholipid bilayer in the presence of amphiphilic drug investigated by neutron reflectometry and quartz crystal microbalance with dissipation monitoring,Biochimica et Biophysica Acta (BBA) - Biomembranes,Volume 1864, Issue 10,2022,183976,ISSN 0005-2736,https://doi.org/10.1016/j.bbamem.2022.183976.

Wang Y, Yu Z, Xiao W, Lu S, Zhang J. Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery. Drug Discov Today. 2021 Mar;26(3):690-703. doi: 10.1016/j.drudis.2020.12.001.

Lee HG, Park YS, Jeong JH, Kwon YB, Shin DH, Kim JY, Rhee YS, Park ES, Kim DW, Park CW. Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate. Drug Des DevelTher. 2019 Jul 23;13:2459-2474. doi: 10.2147/DDDT.S212520.